<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23990724</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1178-2013</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>International journal of nanomedicine</Title><ISOAbbreviation>Int J Nanomedicine</ISOAbbreviation></Journal><ArticleTitle>Evaluation of protective efficacy using a nonstructural protein NS1 in DNA vaccine-loaded microspheres against dengue 2 virus.</ArticleTitle><Pagination><StartPage>3161</StartPage><EndPage>3169</EndPage><MedlinePgn>3161-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/IJN.S49972</ELocationID><Abstract><AbstractText>Dengue virus results in dengue fever or severe dengue hemorrhagic fever/dengue shock syndrome in humans. The purpose of this work was to develop an effective antidengue virus delivery system, by designing poly (dl-lactic-co-glycolic) acid/polyethylene glycol (PLGA/PEG) microspheres using a double-emulsion solvent extraction method, for vaccination therapy based on locally and continuously sustained biological activity. Nonstructural protein 1 (NS1) in deoxyribonucleic acid (DNA) vaccine-loaded PLGA/PEG microspheres exhibited a high loading capacity (4.5% w/w), yield (85.2%), and entrapment efficiency (39%), the mean particle size 4.8 &#x3bc;m, and a controlled in vitro release profile with a low initial burst (18.5%), lag time (4 days), and continued released protein over 70 days. The distribution of protein on the microspheres surface, outer layer, and core were 3.0%, 28.5%, and 60.7%, respectively. A release rate was noticed to be 1.07 &#x3bc;g protein/mg microspheres/day of protein release, maintained for 42 days. The cumulative release amount at Days 1, 28, and 42 was 18.5, 53.7, and 62.66 &#x3bc;g protein/mg microspheres, respectively. The dengue virus challenge in mice test, in which mice received one dose of 20 &#x3bc;g NS1 protein content of microspheres, in comparison with NS1 protein in Al(OH)3 or PBS solution, was evaluated after intramuscular immunization of BALB/c mice. The study results show that the greatest survival was observed in the group of mice immunized with NS1 protein-loaded PLGA/PEG microspheres (100%). In vivo vaccination studies also demonstrated that NS1 protein-loaded PLGA/PEG microspheres had a protective ability; its steady-state immune protection in rat plasma changed from 4,443 &#xb1; 1,384 pg/mL to 10,697 &#xb1; 3,197 pg/mL, which was 2.5-fold higher than that observed for dengue virus in Al(OH)3 at 21 days. These findings strongly suggest that NS1 protein-loaded PLGA/PEG microspheres offer a new therapeutic strategy in optimizing the vaccine incorporation and delivery properties of these potential vaccine targeting carriers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Shih-shiung</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Biomedical Engineering Program, graduate Institute of Applied Science and Technology, and Department of Materials Science and Engineering, National Taiwan University of Science and Technology, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>I-Hsun</ForeName><Initials>IH</Initials></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Po-da</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Ming-kung</ForeName><Initials>MK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Int J Nanomedicine</MedlineTA><NlmUniqueID>101263847</NlmUniqueID><ISSNLinking>1176-9114</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C079340">NS1 protein, Dengue virus type 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102418">poly(lactic-glycolic acid)-poly(ethyleneglycol) copolymer</NameOfSubstance></Chemical><Chemical><RegistryNumber>34346-01-5</RegistryNumber><NameOfSubstance UI="D011098">Polyglactin 910</NameOfSubstance></Chemical><Chemical><RegistryNumber>3WJQ0SDW1A</RegistryNumber><NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008863" MajorTopicYN="Y">Microspheres</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011098" MajorTopicYN="N">Polyglactin 910</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NS1 protein&#x2013;loaded PLGA/PEG microspheres</Keyword><Keyword MajorTopicYN="N">adjuvant</Keyword><Keyword MajorTopicYN="N">dengue virus</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23990724</ArticleId><ArticleId IdType="pmc">PMC3753149</ArticleId><ArticleId IdType="doi">10.2147/IJN.S49972</ArticleId><ArticleId IdType="pii">ijn-8-3161</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guy B, Almond JW. Towards a dengue vaccine: progress to date and remaining challenges. Comp Immunol Microbiol Infect Dis. 2008;31(2&#x2013;3):239&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">17889365</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatch S, Mathew A, Rothman A. Dengue vaccine: opportunities and challenges. IDrugs. 2008;11(1):42&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">18175262</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitchener S, Nissen M, Nasveld P, et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine. 2006;24(9):1238&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pubmed">16213632</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng CH, Liu SJ, Tsai JP, et al. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect. 2009;11(2):288&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">19114121</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol. 2007;5(7):518&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">17558424</ArticleId></ArticleIdList></Reference><Reference><Citation>Simasathien S, Watanaveeradej V. Dengue vaccine. J Med Assoc Thai. 2005;88(Suppl 3):S363&#x2013;S377.</Citation><ArticleIdList><ArticleId IdType="pubmed">16858980</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaney JE, Matro JM, Murphy BR, Whitehead SS. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol. 2005;79(9):5516&#x2013;5528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1082773</ArticleId><ArticleId IdType="pubmed">15827166</ArticleId></ArticleIdList></Reference><Reference><Citation>Amexis G, Young NS. Multiple antigenic peptides as vaccine platform for the induction of humoral responses against dengue-2 virus. Viral Immunol. 2007;20(4):657&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">18158738</ArticleId></ArticleIdList></Reference><Reference><Citation>Heegaard PM, Dedieu L, Johnson N, et al. Adjuvants and delivery systems in veterinary vaccinology: current state and future developments. Arch Virol. 2011;156(2):183&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">21170730</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">19782542</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheerlinck JP, Greenwood DL. Particulate delivery systems for animal vaccines. Methods. 2006;40(1):118&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">16997719</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu SF, Liao CL, Lin YL, et al. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine. 2003;21(25&#x2013;26):3919&#x2013;3929.</Citation><ArticleIdList><ArticleId IdType="pubmed">12922127</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh MK, Chen JL, Chiang CH. Vibrio cholerae-loaded poly(DL lactide co-glycolide) microparticles. J Microencapsul. 2002;19(2):203&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">11837975</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh M, Chiang C. Inactive Vibrio cholerae whole-cell vaccine-loaded biodegradable microparticles: in vitro release and oral vaccination. J Microencapsul. 2004;21(1):91&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">14718189</ArticleId></ArticleIdList></Reference><Reference><Citation>Coombes AG, Yeh MK, Lavelle EC, Davis SS. The control of protein release from poly(DL-lactide co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in oil-in water method. J Control Release. 1998;52(3):311&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">9743451</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Hagan DT. Microparticles and polymers for the mucosal delivery of vaccines. Adv Drug Deliv Rev. 1998;34(2&#x2013;3):305&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">10837683</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadwick S, Kriegel C, Amiji M. Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev. 2010;62(4&#x2013;5):394&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">19931581</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamphorst AO, Guermonprez P, Dudziak D, Nussenzweig MC. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes. J Immunol. 2010;185(6):3426&#x2013;3435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013633</ArticleId><ArticleId IdType="pubmed">20729332</ArticleId></ArticleIdList></Reference><Reference><Citation>Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun. 1991;59(9):2978&#x2013;2986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC258122</ArticleId><ArticleId IdType="pubmed">1879922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: role of physicochemical properties of particulate carriers &#x2013; liposomes and microspheres &#x2013; on the phagocytosis by macrophages. J Control Release. 2002;79(1&#x2013;3):29&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">11853916</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JL, Yeh MK, Chiang CH. The mechanism of surface-indented protein&#x2013;loaded PLGA microparticle formation: the effects of salt (NaCl) on the solidification process. J Microencapsul. 2004;21(8):877&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">15799543</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh MK, Coombes AG, Chen JL, Chiang CH. Japanese encephalitis virus vaccine formulations using PLA lamellar and PLG microparticles. J Microencapsul. 2002;19(5):671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">12433308</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh MK, Davis SS, Coombes AG. Improving protein delivery from microparticles using blends of poly(DL lactide co-glycolide) and poly(ethylene oxide)-poly(propylene oxide) copolymers. Pharm Res. 1996;13(11):1693&#x2013;1698.</Citation><ArticleIdList><ArticleId IdType="pubmed">8956336</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen X, Xue JH, Yu CY, et al. Small envelope protein E of SARS: cloning, expression, purification, CD determination, and bioinformatics analysis. Acta Pharmacol Sin. 2003;24(6):505&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">12791175</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>